×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

 

Dan Lin

Senior Principal Scientist
Cardiometabolic Disorders

Dan joined Amgen in 2004, leading translational research in GPCR drug discovery and pharmacology for metabolic diseases including type 2 diabetes, obesity and hypertension. This work resulted in advanced small molecule drug discovery programs targeting GPCRs in the pancreatic β-cell.  Dan’s research interest has evolved to disease areas with unmet need, with a current focus on mechanisms underlying renal disease, as well as metabolic associated fatty liver disease.  Part of Dan’s research focus is in understanding pathways promoting genetic forms of kidney disease, including focal and segmental glomerulosclerosis and polycystic kidney disease. Dan’s research also utilizes cell biological and in vivo disease models to understand novel pathways contributing to metabolic driven liver disease, with the overarching goal of translating findings into effective therapies.

Featured Publications

Structural basis for pharmacological modulation of the TRPC6 channel. Yonghong Bai, Xinchao Yu, Hao Chen, Daniel Horne, Ryan White, Sue Wu, Paul Lee, Yan Gu, Sudipa Ghimire-Rijal, Daniel C.-H. Lin, Xin Huang.  Elife. 2020 Mar 9;9: e53311. https://pubmed.ncbi.nlm.nih.gov/32149605/

Aminopyrazole–Phenylalanine Based GPR142 Agonists: Discovery of Tool Compound and in Vivo Efficacy Studies.  Ming Yu, Mike Lizarzaburu, Alykhan Motani, Zice Fu, Xiaohui Du, Jiwen (Jim) Liu, Xianyun Jiao, SuJen Lai, Peter Fan, Angela Fu, Qingxiang Liu, Michiko Murakoshi, Futoshi Nara, Kozo Oda, Ryo Okuyama, Jeff D. Reagan, Nobuaki Watanabe, Mami Yamazaki, Yumei Xiong, Ying Zhang, Run Zhuang, Daniel C.-H. Lin, Jonathan B. Houze, Julio C. Medina, and Leping Li.  ACS Med. Chem. Lett., 2013, 4 (9), pp 829–834. https://pubmed.ncbi.nlm.nih.gov/24900757/

Identification and pharmacological characterization of multiple allosteric binding sites on the free fatty acid 1 receptor.  Lin DC, Guo Q, Luo J, Zhang J, Nguyen K, Chen M, Tran T, Dransfield PJ, Brown SP, Houze J, Vimolratana M, Jiao XY, Wang Y, Birdsall NJ, Swaminath G.  Mol Pharmacol. 2012 Nov;82(5):843-59. doi: 10.1124/mol.112.079640. Epub 2012 Aug 2. https://pubmed.ncbi.nlm.nih.gov/22859723/

AMG 837: A Novel GPR40/FFA1 Agonist that Enhances Insulin Secretion and Lowers Glucose Levels in Rodents. Lin DC-H, Zhang J, Zhuang R, Li F, Nguyen K, et al. (2011) PLoS ONE 6(11): e27270. doi: 10.1371/journal.pone.0027270.  https://pubmed.ncbi.nlm.nih.gov/22087278/

Citric acid cycle intermediates as ligands for orphan G-protein-coupled-receptors. W. He, F. Miao, D.C.-H. Lin, R. Schwandner, Z. Wang, J. Gao, J.-L Chen, H. Tian, and L. Ling, Nature, 2004, 429; 188-93. https://pubmed.ncbi.nlm.nih.gov/15141213/

Education

Postdoctoral Research Fellowship, Tularik
Ph.D., Biology, Massachusetts Institute of Technology
B.A., Molecular and Cell Biology, University of California- Berkeley